Advanced breast cancer in pre-menopausal women is often more aggressive when compared to breast cancer in older women. Treatment strategies for younger women are usually extrapolated from data pertaining to post-menopausal patients, with the addition of ovarian function suppression in hormone receptor positive (HR+) disease.
This 30-minute program, endorsed by the Clinical Oncology Society of Australia (COSA), features a summary of HR-positive, HER2-negative metastatic breast cancer, highlights from the MONALESSA-7 trial, including key efficacy and safety data in support of endocrine therapy plus ribociclib as first-line treatment for pre-menopausal women with HR+/HER2- advanced breast cancer.
With a comprehensive case study that focusses on the importance of treatment, management and monitoring of endocrine therapy plus ribociclib, this program also offers expert video commentary from Dr Richard de Boer to help you optimise your practice.